Literature DB >> 30745387

In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus.

Eva Le Run1, Michel Arthur1, Jean-Luc Mainardi2,3.   

Abstract

Mycobacterium abscessus infections are difficult to treat because of their resistance to many antibiotics. In vitro, tedizolid combined with imipenem displayed a moderate synergistic effect (fractional inhibitory concentration index, 0.41) but no bactericidal activity. Intracellularly, tedizolid 2 μg/ml (half of the MIC), corresponding to the peak serum concentration, increased the efficacy of imipenem at 8 and 32 μg/ml. Addition of avibactam and rifabutin, alone or in combination, improved the activity of the imipenem-tedizolid combination.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium abscessus; avibactam; cystic fibrosis; imipenem; rifabutin; tedizolid

Year:  2019        PMID： 30745387      PMCID： PMC6437523          DOI： 10.1128/AAC.01915-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  Inhibition of β-lactamases of mycobacteria by avibactam and clavulanate.

Authors:  Daria Soroka; Clément Ourghanlian; Fabrice Compain; Marion Fichini; Vincent Dubée; Jean-Luc Mainardi; Jean-Emmanuel Hugonnet; Michel Arthur
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

2.  β-Lactamase inhibition by avibactam in Mycobacterium abscessus.

Authors:  Vincent Dubée; Audrey Bernut; Mélanie Cortes; Tiffany Lesne; Delphine Dorchene; Anne-Laure Lefebvre; Jean-Emmanuel Hugonnet; Laurent Gutmann; Jean-Luc Mainardi; Jean-Louis Herrmann; Jean-Louis Gaillard; Laurent Kremer; Michel Arthur
Journal:  J Antimicrob Chemother       Date:  2014-12-18       Impact factor: 5.790

3.  Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.

Authors:  Sylvaine Bastian; Nicolas Veziris; Anne-Laure Roux; Florence Brossier; Jean-Louis Gaillard; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

4.  Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Peter C Appelbaum; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2009-09-16       Impact factor: 5.790

5.  In Vitro and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus.

Authors:  Eva Le Run; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

6.  Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase.

Authors:  Daria Soroka; Vincent Dubée; Olivia Soulier-Escrihuela; Guillaume Cuinet; Jean-Emmanuel Hugonnet; Laurent Gutmann; Jean-Luc Mainardi; Michel Arthur
Journal:  J Antimicrob Chemother       Date:  2013-10-16       Impact factor: 5.790

7.  Treatment of Mycobacterium abscessus Infection.

Authors:  Shannon A Novosad; Susan E Beekmann; Philip M Polgreen; Kate Mackey; Kevin L Winthrop
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

8.  Epidemiology and Predictors of NTM Pulmonary Infection in Taiwan - a Retrospective, Five-Year Multicenter Study.

Authors:  Hung-Ling Huang; Meng-Hsuan Cheng; Po-Liang Lu; Chin-Chung Shu; Jann-Yuan Wang; Jann-Tay Wang; Inn-Wen Chong; Li-Na Lee
Journal:  Sci Rep       Date:  2017-11-24       Impact factor: 4.379

9.  Rifabutin Is Active against Mycobacterium abscessus Complex.

Authors:  Dinah Binte Aziz; Jian Liang Low; Mu-Lu Wu; Martin Gengenbacher; Jeanette W P Teo; Véronique Dartois; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

10.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Authors:  R Andres Floto; Kenneth N Olivier; Lisa Saiman; Charles L Daley; Jean-Louis Herrmann; Jerry A Nick; Peadar G Noone; Diana Bilton; Paul Corris; Ronald L Gibson; Sarah E Hempstead; Karsten Koetz; Kathryn A Sabadosa; Isabelle Sermet-Gaudelus; Alan R Smyth; Jakko van Ingen; Richard J Wallace; Kevin L Winthrop; Bruce C Marshall; Charles S Haworth
Journal:  Thorax       Date:  2016-01       Impact factor: 9.139
View more
  21 in total

1.  Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Select β-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 3.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

4.  Efficacy of Bedaquiline, Alone or in Combination with Imipenem, against Mycobacterium abscessus in C3HeB/FeJ Mice.

Authors:  Vincent Le Moigne; Clément Raynaud; Flavie Moreau; Christian Dupont; Jérôme Nigou; Olivier Neyrolles; Laurent Kremer; Jean-Louis Herrmann
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  In Vitro Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessus.

Authors:  Olumide Martins; Jin Lee; Amit Kaushik; Nicole C Ammerman; Kelly E Dooley; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-09-13       Impact factor: 5.191

6.  In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid.

Authors:  Huiyun Zhang; Wenya Hua; Siran Lin; Yu Zhang; Xinchang Chen; Shiyong Wang; Jiazhen Chen; Wenhong Zhang
Journal:  Infect Drug Resist       Date:  2022-08-25       Impact factor: 4.177

Review 7.  ERS International Congress 2021: highlights from the Respiratory Infections Assembly.

Authors:  Oliver W Meldrum; Kylie B R Belchamber; Kiarina D Chichirelo-Konstantynovych; Katie L Horton; Tetyana V Konstantynovych; Merete B Long; Melissa J McDonnell; Lidia Perea; Alberto L Garcia-Basteiro; Michael R Loebinger; Raquel Duarte; Holly R Keir
Journal:  ERJ Open Res       Date:  2022-05-23

8.  Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors.

Authors:  Khalid M Dousa; Sebastian G Kurz; Magdalena A Taracila; Tracey Bonfield; Christopher R Bethel; Melissa D Barnes; Suresh Selvaraju; Ayman M Abdelhamed; Barry N Kreiswirth; W Henry Boom; Shannon H Kasperbauer; Charles L Daley; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

9.  Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.

Authors:  Matt D Johansen; Wassim Daher; Françoise Roquet-Banères; Clément Raynaud; Matthéo Alcaraz; Florian P Maurer; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  "One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes.

Authors:  David C Nguyen; Khalid M Dousa; Sebastian G Kurz; Sheldon T Brown; George Drusano; Steven M Holland; Barry N Kreiswirth; W Henry Boom; Charles L Daley; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 20.999
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.